IL2 and hypertensive disorder: Our next objective of this study was to determine if blockade of IL-2 with basiliximab (Simulect), a chimeric monoclonal antibody that functions as an immunosuppressive agent, could reduce hypertension in RUPP rats by lowering ET-1 and improve pup weight by inhibiting activated NK cells.